Validation of the revised international prognostic scoring system (IPSS-R) in patients with myelodysplastic syndrome: a multicenter study.
The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transplantation (n=167). We could demonstrate a clear distinction of the IPSS-R risk categories with regard to survival and risk of AML evolution in all patient cohorts. When comparing IPSS-R, IPSS, WHO prognostic scoring system (WPSS) and Duesseldorf score, the best results regarding the ability to predict survival were obtained by the IPSS-R.
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany. Electronic address: Judith.Neukirchen@med.uni-duesseldorf.de.
Judith
J
Neukirchen
Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany.
Michael
M
Lauseker
Department of Hematology, University Lausanne, Switzerland.
Sabine
S
Blum
Department of Hematology, Oncology and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany.
Aristoteles
A
Giagounidis
Department of Hematology and Oncology, Albert-Ludwigs-University, Freiburg, Germany.
Michael
M
Lübbert
Department of Hematology, University of Palermo, Italy.
Samuela
S
Martino
Department of Hematology, University of Palermo, Italy.
Sergio
S
Siragusa
Department of Internal Medicine III, University Hospital Ulm, Germany.
Richard F
RF
Schlenk
Department of Medicine 1, University Hospital Carl Gustav Carus, Dresden, Germany.
Uwe
U
Platzbecker
Department of Medicine III, University Hospital Mannheim, Germany.
Wolf-Karsten
WK
Hofmann
Department of Medicine III, Division for Hematology and Oncology, Klinikum rechts der Isar, Technical University, Munich, Germany.
Katharina
K
Götze
Department of Hematology, AOU "Policlinico - V. Emanuele", Catania, Italy.
Giuseppe A
GA
Palumbo
Division of Hematology and BMT Unit, V. Cervello Hospital, Palermo, Italy.
Silvana
S
Magrin
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Andrea
A
Kündgen
Department of Hematology, Oncology and Clinical Immunology, St. Johannes Hospital, Duisburg, Germany.
Carlo
C
Aul
Department of Human Genetics, Heinrich-Heine-University, Düsseldorf, Germany.
Barbara
B
Hildebrandt
Institute for Medical Information Sciences, Biometry and Epidemiology, Ludwig-Maximilians-Universität, Munich, Germany.
Joerg
J
Hasford
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Guido
G
Kobbe
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Rainer
R
Haas
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Düsseldorf, Germany.
Ulrich
U
Germing
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D005260:Female; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009190:Myelodysplastic Syndromes / Q000473:pathology / Q000628:therapy*; D011379:Prognosis; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D016019:Survival Analysis; D055815:Young Adult
IPSS; IPSS-R; MDS; Prognosis; Survival; WPSS